Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Core Insights - Pfizer Inc. announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315) for adults with moderate to severe atopic dermatitis [1] - The study achieved its primary efficacy endpoint, showing a statistically significant increase in the percentage of participants reaching EASI-75 at Week 16 compared to placebo [1] Study Details - The Phase 2 study evaluated the efficacy of tilrekimig in adults suffering from moderate to severe atopic dermatitis [1] - In Stage 2 of the study, the focus was on assessing the effects of monthly dosing [1]